Abbott $235 Mil. Biocompatibles Stent Purchase Includes Royalties Up To 6%

Abbott's acquisition of the cardiovascular stent business of Biocompatibles International for $234.5 mil. in cash plus royalties will facilitate integration of Abbott's internally-developed, rapamycin analogue stent coating with Biocompatibles' BiodivYsio stent line